WO1999010011A1 - Dried biologically or therapeutically active preparations - Google Patents
Dried biologically or therapeutically active preparations Download PDFInfo
- Publication number
- WO1999010011A1 WO1999010011A1 PCT/AU1998/000682 AU9800682W WO9910011A1 WO 1999010011 A1 WO1999010011 A1 WO 1999010011A1 AU 9800682 W AU9800682 W AU 9800682W WO 9910011 A1 WO9910011 A1 WO 9910011A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- product
- concentrate
- fviii
- factor viii
- protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Definitions
- This invention relates to dried biologically or therapeutically active preparations, and in particular it relates to dried or lyophilised Factor VIII preparations.
- the present invention provides in particular for the stabilisation of such Factor VIII preparations which are to be subjected to a terminal dry heat treatment step, such as heating at
- Classic haemophilia haemophilia A
- AHF antihaemophilic factor
- FVIII Factor VIII
- FVIII is a cofactor for Factor IXa in the activation of Factor X and is crucial for activation of the intrinsic coagulation pathway (Foster and Zimmerman, 1989).
- vWF von Willebrand Factor
- FVIII disulfide-linked multimers between 1 to 20x10 6 daltons.
- the association with vWF serves to stabilise the FVIII molecule in plasma as well as localise the clotting cascade to the site of vascular damage through vWF adhesion to the activated platelet surface (Weiss 1977).
- the molecular weight of FVIII in plasma ranges between 250,000 to 300,000 daltons. It is composed of heavy and light chains with molecular weights of approximately 90 and 80 kDa respectively, separated by a heavily glycosylated ⁇ - domain region of approximately 130 kDa (Fulcher and Zimmerman 1982, Rotblat et al.
- FVIII is susceptible to proteolytic cleavage by thrombin and Factor Xa. This . serves to remove the ⁇ -domain, resulting in a conformational change whereby the heavy and light chains become linked by calcium ion binding. This cleavage correlates with an increase in functional activity and represents the activated form of the molecule, FVIIIa (Eaton et al. 1986, Fulcher et al. 1985, Andersson et al. 1986, 0 Fay et al. 1986, Pittman and Kaufman 1986).
- FVIIIa Once FVIIIa has fulfilled its roles, it is proteolytically cleaved further by either thrombin, FACTOR Xa or activated protein C, correlating with loss of functional activity. Peptides range from 43 kDa to 80 kDa form, depending on the participating 5 enzyme (Eaton et al. 1987).
- the cloning of human FVIII gene and the expression of active recombinant FVIII have been reported.
- the cDNA codes for a single chain FVIII consist of 2332 amino acid residues with a molecular weight of 264,763 Da prior to giycosylation and the 0 glycosylated form of approximately 330 kDa (Toole et al. 1984, Gitschier et al. 1984, Rotblat et al. 1985). It has been shown that calcium is necessary for maintaining the association of FVIII heavy and light chains, and the removal of calcium from FVIII preparations has been demonstrated to result in loss of procoagulant activity (Fass et al. 1982, Andersson et al. 1986, Mikaelsson et al. 1983).
- the reconstitution of FVIII 5 activity from isolated heavy and light chains requires the presence of divalent cations, with Mn 2+ having the strongest effect followed by Ca 2+ and Co 2+ (Fay 1988).
- haemophilia A The incidence of haemophilia A is approximately 1 in 10,000 males, by the inheritance of an autosomal recessive pattern (Gitschier et al. 1984). Without 0 treatment, haemophiliacs experience haemorrhage into joints and muscles, are easily bruised, and suffer prolonged and potentially fatal postoperative haemorrhages. Restoration of plasma FVIII levels to greater than 1 % of normal with plasma-derived commercial concentrates containing FVIII significantly reduces disease symptoms and markedly improves the quality of life for afflicted individuals (Aronson 1990, Esmon et al. 1990).
- cryoprecipitate or FVIII concentrates may result in functional and phenotypical immune deficiencies (Lederman et al. 1983, Menitove et al. 1983, Schulman 1991 , Allersma et 1996). These immune deficiencies include impaired monocyte and phagocyte function as well as abnormalities of T cell subsets, irrespective of HIV infection (Moffat et al. 1985).
- FVIII concentrates can be classified on the basis of specific activity (expressed in lU/mg total protein in the final product state) as either intermediate (1 -5 lU/mg protein), high (10-200 lU/mg) or very high purity (1000-3000 lU/mg). Intermediate purity products are prepared by precipitation reactions and often contain high levels
- albumin is often added back into these products at the end of the manufacturing process to stabilise the product and to avoid Factor VIII dispersion on the glass wall of the container resulting in a lower specific activity than several high purity products. If the albumin content is subtracted from high or very high purity Factor VIII concentrates, figures in the range of 10-200 lU/mg or 1000-3000
- Terminal dry heat treatment is a popular methodology introduced in the late 1980s to ensure a high degree of viral safety (Winkelman et al. 1989).
- Coagulation factor concentrates that are heated at 80 °C for 72 hours have an excellent safety record (Rizza et al. 1993, Cash 1988, Skidmore et al. 1990).
- sugars as stabilisers of biologically active proteins has been previously disclosed in US patents 2,826,533 (1958) and 4,089,944 (1978). Since the
- FVIII molecule is a heat sensitive protein
- FVIII concentrates of intermediate purity have been stabilised with different concentrations of various sugars, lyophilised and exposed to dry heat regimes of 80° C for 72 hours (Roberts 1995).
- the synthetic amino acid mixture was used for the large scale manufacture of an intermediate FVIII concentrate (1 lU/mg) using controlled pore glass adsorption chromatography. Heat stability of the freeze dried material was tested and no loss of FVIII activity was shown after 30 hours at 70 °C compared with other intermediate purity concentrate preparations tested which exhibited approximately 25% of activity after only hours at 70°C and solubility was significantly impaired (Margolis et al. 1984, Austen 1979). Similar FVIII preparations have been stabilised by addition of the synthetic amino acid mixture (1.6% w/v) in the final product.
- the lyophilised material heated at 60°C for 72 hours reduced the FVIII loss to less than 10% compared with a non-amino acid stabilised concentrate, which resulted in the loss of 30% of FVIII: C activity (McGrath et al. 1985).
- FVIII is only a small fraction of the protein contained in the concentrates (i.e. ⁇ 1 %), the majority being fibrinogen, immunoglobulin, fibronectin and many others. The presence of such proteins has also been shown to help stabilise the FVIII molecule over the terminal dry heat stage.
- albumin can be considered as an essential component of the protein overload and thereby of the immune depression observed in heavily-infused patients is still a matter of controversy. Cohn Fractionation Albumin solutions used to stabilise high purity FVIII concentrates are unlikely to be more than 95% pure and so trace amounts of other proteins may therefore be added back into the FVIII concentrates. However, this practice largely defeats the purpose of purification.
- FVIII concentrates have been well established using sodium citrate as an anticoagulant in plasma fractionation.
- Citrate was also reported to have a marked stabilising effect on early preparations of chromatographically purified FVIII concentrates (Hynes et al. 1969) which helped establish the use of 20mM trisodium citrate in commercial FVIII concentrates (Newman et al. 1971).
- FVIII activity shows a biphasic deterioration in the presence of citrate (Preston 1967).
- the present invention provides improved stabilising compositions which are particularly, but not exclusively, directed to the stabilisation of high and very high purity Factor VIII concentrates as discussed above.
- the present invention also provides stabilising compositions for these concentrates which avoid the necessity for adding back albumin, although albumin may still be added if desired and acceptable.
- a dried, heat-treated product comprising a heat labile, biologically or therapeutically active protein or peptide preparation, and a stabilising effective amount of a composition comprising sucrose, trehalose and at least one amino acid.
- the present invention provides a method of preparing a dried, heat-treated product comprising a heat labile, biologically or therapeutically .
- active protein or peptide preparation which comprises (i) adding a stabilising effective amount of a composition comprising sucrose, trehalose and at least one amino acid to said protein or peptide preparation; (ii) drying said admixture; and (iii) heat-treating said dried product.
- the invention provides a composition for use in the stabilisation of a heat labile, biologically or therapeutically active protein or peptide preparation, comprising sucrose, trehalose and at least one amino acid.
- drying and “dried” are used herein in the broad sense to refer to removal of water from an aqueous product and products obtained thereby, and include in particular the freeze drying process (also known as lyophilisation).
- heat-treating and “heat-treated” are used herein to refer to methods of heat treatment in order to reduce or abolish a virus load in a biologically or therapeutically active product and products obtained thereby, and include dry heat treatment at greater than 75°C for up to 72 hours, more particularly dry heat treatment at 80 °C for 72 hours.
- the present invention comprises a dried Factor
- Factor VIII preparation comprising a Factor VIII concentrate, and a stabilising effective amount of a composition comprising sucrose, trehalose and at least one amino acid.
- the Factor VIII concentrate is a high purity (10 - 200 lU/mg) or very high purity (1000-3000 lU/mg) product.
- References herein to a "high purity” or “very high purity” Factor VIII concentrate should be understood as referencing to the purity of the concentrate prior to the addition of a protein stabiliser.
- the protein or peptide preparation may be a von Willebrand Factor concentrate.
- the stabilising composition in accordance with the present invention may also comprise albumin, particularly human serum albumin.
- the formulations of the present invention have the potential to provide another alternative to the adding back of protein such as human serum albumin (HSA) as a stabilising agent for high purity FVIII concentrates.
- HSA human serum albumin
- albumin in the composition of this invention is optional, the addition of albumin is not an ideal option because it adds a complex component to the product formulation.
- the formulations detailed in this invention relate to defined chemical additives containing specific components designed to prevent adsorption, and to maintain the stability and solubility of high purity FVIII concentrates exposed to heat treatment regimes, in particular the dry heat treatment of lyophilised product heated at 80° C for 72 hours.
- Trehalose as disclosed in WO 96/22107 may be used to stabilise a dried blood factor composition which undergoes heat treatment at pasteurisation temperatures (60° C).
- the amount of trehalose used in some of the formulations in the present invention when used alone is insufficient to produce a stabilising effect at temperatures greater than 60°C (i.e. 80°C for 72 hours).
- trehalose in combination with other chemical additives, sugars and amino acids as disclosed in this invention provides significant stability to high purity FVIII concentrates undergoing severe dry heat treatment.
- the disclosed formulations provide a method of preparing aqueous solutions containing FVIII, which may be freeze dried at temperatures greater than 25°C.
- sucrose is preferably present in amounts of from 0.5 to 10% by weight, more preferably from 2.5 to 5% by weight.
- trehalose is preferably present in amounts of from 0.5 to 5% by weight, more preferably from 1.25 to 2.5% by weight.
- the amino acid which is incorporated into the stabilising composition is preferably lysine, and the amino acid is preferably incorporated in a molar amount of from 0.05 to 1M, more preferably 0.1 to 0.5M.
- the amino acid may be incorporated as a mixture of amino acids, particularly the mixture available commercially as Synthamin 17, or one or more of the amino acids present in Synthamin 17.
- Synthamin 17 is a formulation of amino acids as follows:
- L-Phenylalanine (560) L-Serine (500) L-Threonine (420) Glycine (1030)
- Such a mixture of amino acids is preferably used in the stabilising composition of the present invention in amounts of from 0.5 to 5% by weight, more preferably from 2 to 3% by weight.
- albumin such as human serum albumin
- albumin may optionally be incorporated in the stabilising composition of the present invention.
- albumin may be present in an amount of from 0.1 to 10 mg/mL of the Factor VIII concentrate prior to freeze drying.
- compositions of the present invention may also be used in the stabilisation of other biologically or therapeutically active preparations, particularly those which are to be dried or lyophilised and subsequently treated to dry heat treatment as a viral inactivation step.
- biologically or therapeutic preparations include, for example, other blood, plasma or serum fractions, enzymes, antibodies, antigens, vaccine components and the like.
- This Example relates to a stabilised, dried Factor VIII preparation comprising a high purity Factor VIII concentrate.
- Fresh frozen plasma (FFP) is thawed at temperatures below 5°C and the FVlll- rich cryoprecipitate is collected by centrifugation.
- the FVIII is extracted with Tris (hydroxymethyl) methylamine (Tris) buffer.
- Tris hydroxymethyl methylamine
- Levels of unwanted proteins, principally fibrinogen, fibronectin, immunoglobulin and albumin, are reduced by precipitation with heparin followed by reprecipitation of FVIII with sodium chloride/glycine buffer.
- the purified FVIII is redissolved in a sodium chioride-Tris-citrate buffer containing sucrose and a low level of calcium chloride. The dissolved precipitate is filtered, treated with solvent/detergent and incubated.
- the mixture is then filtered and chromatographed on a Sephacryl S400 column pre-equilibrated in the same buffer.
- the FVlll-rich eluate (>50 lU/mg total protein) is then concentrated by ultrafiltration against the same buffer and chemical stabilisers added to the retentate.
- the bulk formulated concentrate is sterile filtered, dispensed, freeze dried and heat treated at 80°C for 72 hours. Freeze Drying/Dry Heat Treatment
- the freeze drying cycle proceeds under conditions of programmed temperature/vacuum/timing for approximately 100 hours.
- the formulated product is loaded into a freeze dryer and the shelves cooled to -50°C.
- the vacuum is applied and the temperature ramped up to 50°C.
- the finished lyophilised product is then heated in a hot air oven at 80° C for 72 hours.
- FVIII procoagulant activity was measured throughout the process using a chromogenic assay kit (Chromogenix, Sweden).
- the FVIII concentrates used in the experiments detailed in this invention were formulated in a sodium chloride/Tris/citrate buffer containing sucrose and a low level of calcium chloride.
- the stability of FVIII concentrate using this buffering system has been well established.
- this formulation alone provided little protection of the FVIII molecule in the high purity product over the terminal dry heat treatment step.
- a 33% loss of FVIII activity was reported, compared with the intermediate purity product in the same buffer where only 13% of the FVIII activity was lost over the same step, highlighting the protective effect of the high levels of protein contained in this concentrate.
- the high purity product stabilised with added albumin only lost 21% FVIII activity.
- the post dry heated results also showed that additional sugars such as sorbitol, maltose and sucrose alone produced little or no stabilisation over the dry heat treatment step.
- Significant losses of FVIII activity were observed from the formulated bulk concentrate to post terminal dry heat treatment.
- the post drying results showed that it was not possible to dry heat the purity concentrate successfully when trehalose (45% loss of FVIII activity) or Synthamin 17 (25% loss of FVIII activity) were also alone.
- Trehalose in combination with sucrose also produced significant losses in FVIII activity (61%).
- a composition of trehalose in combination with sucrose and lysine and with a composition of sucrose, trehalose, lysine in combination with other amino acids (Synthamin 17), it was possible to dry heat FVIII successfully in the absence of human serum albumin.
- Aronson D The development of the technology and capacity for the production of factor VIII for the treatment of haemophilia A. Transfusion (1990); 30:8:748-58.
- Fay PJ Anderson MT, Chavin SI, Marder VJ. The size of human VIII heterodimers and the effects produced by thrombin. Biochem. Biophys. >Acfa (1986); 871:268-78. Fay P. Reconstitution of human factor VIII from isolated subunits. Arch. Biochem. Biophys. (1988); 262(2): 525-31.
- Fulcher CA Zimmerman TS. Characterisation of the human factor VIII procoagulant protein with a heterologous precipitating antibody. Proc.Natl. Acad. Sci. (1982); 798:1648-52.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ503034A NZ503034A (en) | 1997-08-25 | 1998-08-25 | Dried biologically or therapeutically active Factor VIII preparations |
CA002301514A CA2301514A1 (en) | 1997-08-25 | 1998-08-25 | Dried biologically or therapeutically active preparations |
EP98938550A EP1009438A1 (en) | 1997-08-25 | 1998-08-25 | Dried biologically or therapeutically active preparations |
AU87231/98A AU8723198A (en) | 1997-08-25 | 1998-08-25 | Dried biologically or therapeutically active preparations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPO8719A AUPO871997A0 (en) | 1997-08-25 | 1997-08-25 | Dried biologically or therapeutically active preparations |
AUPO8719 | 1997-08-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999010011A1 true WO1999010011A1 (en) | 1999-03-04 |
Family
ID=3803005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1998/000682 WO1999010011A1 (en) | 1997-08-25 | 1998-08-25 | Dried biologically or therapeutically active preparations |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1009438A1 (en) |
AU (1) | AUPO871997A0 (en) |
CA (1) | CA2301514A1 (en) |
NZ (1) | NZ503034A (en) |
PL (1) | PL338856A1 (en) |
WO (1) | WO1999010011A1 (en) |
ZA (1) | ZA987633B (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001270900A (en) * | 2000-03-23 | 2001-10-02 | Nihon Pharmaceutical Co Ltd | Method for inactivating virus in fibrinogen |
EP1273306A1 (en) * | 2000-03-31 | 2003-01-08 | Kirin Beer Kabushiki Kaisha | Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability |
EP1428537A1 (en) * | 2001-08-29 | 2004-06-16 | Chugai Seiyaku Kabushiki Kaisha | Stabilized preparations containing antibody |
FR2857267A1 (en) * | 2003-07-09 | 2005-01-14 | Lab Francais Du Fractionnement | STABILIZING AND SOLUBILIZING FORMULATION FOR CRYOPRECIPITABLE PROTEINS. |
EP1712223A1 (en) * | 2004-06-25 | 2006-10-18 | Green Cross Holdings | Pharmaceutical preparation of recombinant factor VIII lyophilized without albumin as a stabilizer |
WO2008155529A1 (en) * | 2007-06-16 | 2008-12-24 | Enigma Diagnostics Limited | Compositions |
EP2150537A2 (en) * | 2007-06-01 | 2010-02-10 | ACOLOGIX, Inc. | High temperature stable peptide formulation |
US9120873B2 (en) | 2008-08-21 | 2015-09-01 | Octapharma Ag | Recombinantly produced human factor VIII and IX |
US10806770B2 (en) | 2014-10-31 | 2020-10-20 | Monash University | Powder formulation |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4297344A (en) * | 1979-04-25 | 1981-10-27 | Behringwerke Aktiengesellschaft | Blood coagulation factors and process for their manufacture |
EP0077870A2 (en) * | 1981-10-28 | 1983-05-04 | Green Cross Corporation | Process for heat treatment of aqueous solution containing human blood coagulation factor VIII |
US4562072A (en) * | 1982-10-09 | 1985-12-31 | Behringwerke Aktiengesellschaft | Process for the pasteurization of antihemophilic cryoprecipitate (AHC) and antihemophilic cryoprecipitate prepared thereby |
US4623717A (en) * | 1980-03-05 | 1986-11-18 | Miles Laboratories, Inc. | Pasteurized therapeutically active protein compositions |
WO1987000196A1 (en) * | 1985-07-09 | 1987-01-15 | Quadrant Bioresources Limited | Protection of proteins and the like |
EP0599543A1 (en) * | 1992-11-19 | 1994-06-01 | Tanabe Seiyaku Co., Ltd. | Pharmaceutical preparation comprising fat emulsion of fat microparticles |
WO1996022107A1 (en) * | 1995-01-19 | 1996-07-25 | Quadrant Holdings Cambridge Limited | Dried blood factor composition comprising trehalose |
-
1997
- 1997-08-25 AU AUPO8719A patent/AUPO871997A0/en not_active Abandoned
-
1998
- 1998-08-24 ZA ZA987633A patent/ZA987633B/en unknown
- 1998-08-25 NZ NZ503034A patent/NZ503034A/en unknown
- 1998-08-25 EP EP98938550A patent/EP1009438A1/en not_active Withdrawn
- 1998-08-25 WO PCT/AU1998/000682 patent/WO1999010011A1/en not_active Application Discontinuation
- 1998-08-25 CA CA002301514A patent/CA2301514A1/en not_active Abandoned
- 1998-08-25 PL PL98338856A patent/PL338856A1/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4297344A (en) * | 1979-04-25 | 1981-10-27 | Behringwerke Aktiengesellschaft | Blood coagulation factors and process for their manufacture |
US4623717A (en) * | 1980-03-05 | 1986-11-18 | Miles Laboratories, Inc. | Pasteurized therapeutically active protein compositions |
EP0077870A2 (en) * | 1981-10-28 | 1983-05-04 | Green Cross Corporation | Process for heat treatment of aqueous solution containing human blood coagulation factor VIII |
US4562072A (en) * | 1982-10-09 | 1985-12-31 | Behringwerke Aktiengesellschaft | Process for the pasteurization of antihemophilic cryoprecipitate (AHC) and antihemophilic cryoprecipitate prepared thereby |
WO1987000196A1 (en) * | 1985-07-09 | 1987-01-15 | Quadrant Bioresources Limited | Protection of proteins and the like |
EP0599543A1 (en) * | 1992-11-19 | 1994-06-01 | Tanabe Seiyaku Co., Ltd. | Pharmaceutical preparation comprising fat emulsion of fat microparticles |
WO1996022107A1 (en) * | 1995-01-19 | 1996-07-25 | Quadrant Holdings Cambridge Limited | Dried blood factor composition comprising trehalose |
Non-Patent Citations (3)
Title |
---|
DERWENT ABSTRACT, Accession No. 94-022829/03, Class B04; & JP,A,05 331 071 (ASAHI CHEM INC CO LTD) 14 December 1993. * |
PATENT ABSTRACTS OF JAPAN; & JP,A,06 321 805 (ASAHI CHEM IND CO LTD) 22 November 1994. * |
PATENT ABSTRACTS OF JAPAN; & JP,A,08 187 095 (TOYOBO CO. LTD.). * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001270900A (en) * | 2000-03-23 | 2001-10-02 | Nihon Pharmaceutical Co Ltd | Method for inactivating virus in fibrinogen |
US7282219B2 (en) | 2000-03-31 | 2007-10-16 | Kirin Beer Kabushiki Kaisha | Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability |
EP1273306A1 (en) * | 2000-03-31 | 2003-01-08 | Kirin Beer Kabushiki Kaisha | Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability |
EP1273306A4 (en) * | 2000-03-31 | 2005-06-22 | Kirin Brewery | Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability |
EP1428537A1 (en) * | 2001-08-29 | 2004-06-16 | Chugai Seiyaku Kabushiki Kaisha | Stabilized preparations containing antibody |
US7682608B2 (en) | 2001-08-29 | 2010-03-23 | Chugai Seiyaku Kabushiki Kaisha | Stabilized preparations containing antibody |
EP1428537A4 (en) * | 2001-08-29 | 2005-11-09 | Chugai Pharmaceutical Co Ltd | Stabilized preparations containing antibody |
WO2005004901A1 (en) * | 2003-07-09 | 2005-01-20 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Method for stabilizing a cryoprecipitate of plasmatic proteins for being subjected to a viral inactivation thermal treatment |
FR2857267A1 (en) * | 2003-07-09 | 2005-01-14 | Lab Francais Du Fractionnement | STABILIZING AND SOLUBILIZING FORMULATION FOR CRYOPRECIPITABLE PROTEINS. |
AU2004255503B2 (en) * | 2003-07-09 | 2010-12-16 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Method for stabilizing a cryoprecipitate of plasmatic proteins for being subjected to a viral inactivation thermal treatment |
EP1712223A1 (en) * | 2004-06-25 | 2006-10-18 | Green Cross Holdings | Pharmaceutical preparation of recombinant factor VIII lyophilized without albumin as a stabilizer |
EP2150537A2 (en) * | 2007-06-01 | 2010-02-10 | ACOLOGIX, Inc. | High temperature stable peptide formulation |
EP2150537A4 (en) * | 2007-06-01 | 2010-09-22 | Acologix Inc | High temperature stable peptide formulation |
US7879805B2 (en) | 2007-06-01 | 2011-02-01 | Acologix, Inc. | High temperature stable peptide formulation |
WO2008155529A1 (en) * | 2007-06-16 | 2008-12-24 | Enigma Diagnostics Limited | Compositions |
US9120873B2 (en) | 2008-08-21 | 2015-09-01 | Octapharma Ag | Recombinantly produced human factor VIII and IX |
US10806770B2 (en) | 2014-10-31 | 2020-10-20 | Monash University | Powder formulation |
Also Published As
Publication number | Publication date |
---|---|
NZ503034A (en) | 2001-02-23 |
CA2301514A1 (en) | 1999-03-04 |
PL338856A1 (en) | 2000-11-20 |
EP1009438A1 (en) | 2000-06-21 |
ZA987633B (en) | 1999-02-25 |
AUPO871997A0 (en) | 1997-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10881717B2 (en) | Method for improving the stability of purified Factor VIII after reconstitution | |
KR100303872B1 (en) | Compositions containing coagulation factor formulations, methods for their preparation and use of surfactants as stabilizers | |
AU780415B2 (en) | Stable Factor VIII compositions | |
CA2210038C (en) | Stabilized albumin-free recombinant factor viii preparation having a low sugar content | |
JP4879104B2 (en) | Highly concentrated, lyophilized, and liquid, factor IX formulation | |
JP2000506869A (en) | Stable factor VIII / ▲ lower V ▼ WF complex | |
NO324064B1 (en) | Pharmaceutical composition comprising vWF propeptide and method of preparation and use thereof | |
EP1009438A1 (en) | Dried biologically or therapeutically active preparations | |
JP2005511038A (en) | Variant of factor VIII C2 domain | |
AU8723198A (en) | Dried biologically or therapeutically active preparations | |
AU677797C (en) | Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer | |
AU2015258240A1 (en) | Method of improving the stability of purified factor viii after reconstitution |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2301514 Country of ref document: CA Kind code of ref document: A Ref document number: 2301514 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 503034 Country of ref document: NZ |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 87231/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998938550 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09486316 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998938550 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998938550 Country of ref document: EP |